Company intelligence / Profile preview

Aegera Therapeutics

Ownership: Private
Employees: ~35
Development stage: Phase 2

Overview

Aegera Therapeutics was a clinical stage biotechnology company that had three programs in clinical development, two for oncology and one for neuropathic pain. Their lead candidate AEG35156, a XIAP antisense oligonucleotide, showed promising results in Phase 1/2 trials for AML patients not responding to frontline induction therapy. The company was acquired by Pharmascience in 2011.

Therapeutic areas: OncologyImmunologyNeurologyHematology
Modalities: Antisense Oligonucleotides
Industry: Biotech

Drug pipeline

3 assets

AEG35156

Phase 2

Indications: Cancer

2 more assets in the full pipeline.

Request access →

Partnerships

Leukemia and Lymphoma Society

Beyond the preview

Go deeper on Aegera Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aegera Therapeutics.

Explore the full profile